JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia
JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia
复制标题
JACLS ALL-02 SR 方案降低强度化疗对低危儿童急性淋巴细胞白血病患者产生了良好的疗效
DOI：
10.1007/s12185-022-03315-x
复制
发表时间：
2022
影响因子：
2.1
通讯作者：
Suenobu Souichiら
中科院分区：
文献类型：
--
作者：
Takahashi Yoshihiro;Suenobu Souichiら
急性淋巴细胞白血病（ALL）是最常见的儿童癌症。随着儿童ALL的总体治愈率的提高，降低总体治疗强度，同时仍确保良好的结局对于低风险患者至关重要。我们报告了前瞻性日本儿童白血病研究协会（JACLS）ALL-02研究中按照标准风险方案治疗的患者的结局，该研究在2002年至2008年期间对1-18岁的新诊断ALL患者进行。在1138例前体B细胞ALL患者中，388例（34.1%）被分配至本方案。尽管总体治疗强度低于大多数当代方案，但仍取得了良好的结局：4年无事件生存率（EFS）为92.3%，4年总生存率为98.2%。涉及三三体（染色体4、10和17的三体）或ETV 6-RUNX 1的高超二倍体（HHD）患者的结局更好（4年EFS分别为97.6%和100%）。该方案的独特特征包括选择初始WBC计数低、早期治疗反应良好的低风险患者，以及在维持剂量密度的同时减少化疗药物的累积剂量。在日本，我们目前正在研究该方案的可行性，同时将微小残留病纳入患者分层策略。
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. As overall cure rates of childhood ALL have improved, reduction of overall treatment intensity while still ensuring excellent outcomes is imperative for low-risk patients. We report the outcomes of patients treated following the standard-risk protocol from the prospective Japan Association of Childhood Leukemia Study (JACLS) ALL-02 study, which was conducted between 2002 and 2008 for patients with newly diagnosed ALL aged 1–18 years. Of 1138 patients with B-cell precursor ALL, 388 (34.1%) were allocated to this protocol. Excellent outcomes were achieved despite the overall treatment intensity being lower than that of most contemporary protocols: 4 years event-free survival (EFS) was 92.3% and 4 years overall survival 98.2%. Patients with high hyperdiploidy (HHD) involving triple trisomy (trisomy of chromosomes 4, 10, and 17) or ETV6-RUNX1 had even better outcomes (4 years EFS 97.6% and 100%, respectively). Unique characteristics of this protocol include a selection of low-risk patients with a low initial WBC count and good early treatment response and reduction of cumulative doses of chemotherapeutic agents while maintaining dose density. In Japan, we are currently investigating the feasibility of this protocol while incorporating minimal residual disease into the patient stratification strategy.
登录
查看更多内容
影响因子：
45.3
作者：
Dixon, Stephanie B.;Chen, Yan;Nathan, Paul C.
通讯作者：
Nathan, Paul C.
儿童癌症成年幸存者的慢性健康状况
DOI：
10.1016/s0084-3954(08)70515-3
发表时间：
2008
期刊：
Yearbook of Pediatrics
影响因子：
--
作者：
J. Stockman
通讯作者：
J. Stockman
DOI：
10.1056/nejmoa0900386
发表时间：
2009-06-25
期刊：
The New England journal of medicine
影响因子：
--
作者：
Pui CH;Campana D;Pei D;Bowman WP;Sandlund JT;Kaste SC;Ribeiro RC;Rubnitz JE;Raimondi SC;Onciu M;Coustan-Smith E;Kun LE;Jeha S;Cheng C;Howard SC;Simmons V;Bayles A;Metzger ML;Boyett JM;Leung W;Handgretinger R;Downing JR;Evans WE;Relling MV
通讯作者：
Relling MV
影响因子：
45.3
作者：
Pieters, Rob;de Groot-Kruseman, Hester;Van Dongen, Jacques
通讯作者：
Van Dongen, Jacques
影响因子：
51.1
作者：
Place, Andrew E.;Stevenson, Kristen E.;Silverman, Lewis B.
通讯作者：
Silverman, Lewis B.